Patents by Inventor John E. Donello

John E. Donello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20230062049
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 2, 2023
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
    Publication number: 20220402866
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 8, 2021
    Publication date: December 22, 2022
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES
    Publication number: 20220233505
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Application
    Filed: April 14, 2022
    Publication date: July 28, 2022
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
    Publication number: 20220202777
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: April 13, 2021
    Publication date: June 30, 2022
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
    Patent number: 11331306
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: May 17, 2022
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL
    Publication number: 20220008393
    Abstract: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: February 18, 2021
    Publication date: January 13, 2022
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
    Patent number: 11208377
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 28, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 11046644
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 10993931
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: May 4, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
    Patent number: 10899780
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: January 26, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES
    Publication number: 20210008085
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Application
    Filed: September 22, 2020
    Publication date: January 14, 2021
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES
    Publication number: 20210000846
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Application
    Filed: September 22, 2020
    Publication date: January 7, 2021
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES
    Publication number: 20200390747
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Application
    Filed: January 14, 2020
    Publication date: December 17, 2020
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20200330428
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: November 25, 2019
    Publication date: October 22, 2020
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
    Patent number: 10799518
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: October 13, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES
    Publication number: 20200246360
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Application
    Filed: September 10, 2019
    Publication date: August 6, 2020
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL
    Publication number: 20200206193
    Abstract: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: August 7, 2019
    Publication date: July 2, 2020
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT
    Publication number: 20200171026
    Abstract: Prostacyclin (PGI2) analogues which are agonists of the prostacyclin receptor (PI) are demonstrated to activate lipolytic activity in adipocytes. Also described are pharmaceutical compositions and methods for using the PGI2 receptor agonists to reduce subcutaneous adipose tissue and to treat or reduce symptoms of obesity-related diseases or disorders such as diabetes mellitus, fatty liver disease and cardiovascular disease.
    Type: Application
    Filed: July 27, 2018
    Publication date: June 4, 2020
    Inventors: Yong-Xin Li, Neil J. Poloso, John E. Donello, Qianyong Liu
  • SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20200109110
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 9, 2020
    Inventors: HAIQING YUAN, RICHARD L. BEARD, XIAOXIA LIU, JOHN E. DONELLO, VEENA VISWANATH, MICHAEL E. GARST
  • Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
    Patent number: 10555933
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: February 11, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil